Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Contributed by: Business Wire

Logo

Tags

Health

Consumer

Women

Other Health

Pharmaceutical

Biotechnology

Dermavant

More Like This

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Innovaderm, a Key Collaborator in Clinical and Study Development for Recently Published Phase 1 Atopic Dermatitis Study

Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

PR Newswire associated0

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

PR Newswire associated0

Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada